Conditional marketing authorisation in the EU: Manging the path from approval to full licence

InConversation talks about conditional marketing authorisation − and how the work starts after approval – with Catherine Moncad

Conditional marketing authorisation (CMA) can help bring innovative medicines to patients with high unmet medical need sooner. But for sponsors, particularly emerging biotechs and first-time marketing authorisation holders, approval is only the beginning.

In this latest episode of the RegRapPod − InConversation series, Regulatory Rapporteur Managing Editor Claire McDermott speaks with Catherine Moncad, Vice President of Regulatory Services at TMC Pharma Services Ltd, about the realities of planning for, securing and maintaining a conditional marketing authorisation in the EU.